Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
A phase 1/2 trial of Ribociclib, Fulvestrant in small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.
Overview
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06726148 by Novartis Pharmaceuticals, with 280 participants planned, started 2025-04-03 and due to reach its primary completion in 2028-09-25. Interventions recorded: ECI830, ribociclib, fulvestrant. Conditions listed: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Shares Fulvestrant, Novartis.
- TrialA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Shares Ribociclib, Fulvestrant.
- TrialPlatform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares Ribociclib, Novartis, Small-cell lung cancer.
- TrialA Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Shares Novartis, Small-cell lung cancer.
- TrialStudy of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Shares Ribociclib, Novartis.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Ribociclib, Fulvestrant.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Ribociclib, Fulvestrant.
- TrialPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Shares Ribociclib, Fulvestrant.